PLx Pharma Winddown Corp. Annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect in USD from 2019 to 2021

Taxonomy & unit
us-gaap: USD
Description
Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
Summary
PLx Pharma Winddown Corp. quarterly/annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect history and growth rate from 2019 to 2021.
  • PLx Pharma Winddown Corp. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect for the quarter ending March 31, 2022 was -$16.9M, a 127% decline year-over-year.
  • PLx Pharma Winddown Corp. annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect for 2021 was $46.9M, a 456% increase from 2020.
  • PLx Pharma Winddown Corp. annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect for 2020 was $8.45M.
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, Annual (USD)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2021 $46.9M +$38.5M +456% Jan 1, 2021 Dec 31, 2021 10-K 2022-03-11
2020 $8.45M +$8.7M Jan 1, 2020 Dec 31, 2020 10-K 2022-03-11
2019 -$249K Jan 1, 2019 Dec 31, 2019 10-K 2021-03-12
* An asterisk sign (*) next to the value indicates that the value is likely invalid.